Freenome is a biotech company dedicated to transforming cancer detection through its innovative blood tests. Utilizing a multiomics platform that leverages both tumor and non-tumor signals combined with machine learning, Freenome aims to identify cancer at its earliest and most treatable stages. Founded in 2014, the company has developed its first screening test for colorectal cancer and advanced adenomas, marking a significant step in its mission to enhance cancer screening accessibility and improve patient outcomes. With a focus on collaboration and respect, Freenome cultivates a high-performing culture where diverse perspectives contribute to breakthroughs in cancer detection. The company is committed to driving clinical and operational evidence that underscores the importance of early detection in saving lives.